PDCD1 and myasthenia gravis: In September 2025, following radiotherapy and a single dose of serplulimab (a programmed cell death protein 1 inhibitor, PD-1), the patient developed clinical symptoms including ptosis, a positive fatigue test, and a positive neostigmine test, suggestive of myasthenia gravis.